Computational Design of DNA and mRNA Vaccine Candidates Using 28 Human Metapneumovirus Epitopes
Background: Finding Vaccine Candidates in Viral Sequences
A computational study selected 28 epitopes from six structural proteins of human metapneumovirus (HMPV) and designed DNA and messenger RNA (mRNA) vaccine candidates. The researchers computationally assessed the antigenicity and potential immune responses of constructs combining multiple epitopes. The provided abstract reports no results demonstrating protection against infection in animals or humans.
HMPV is a respiratory pathogen that mainly affects children, immunocompromised people, and older adults. The reverse vaccinology approach used by the researchers starts with viral sequences to identify candidate regions the immune system may recognize. An epitope is a specific part of an antigen recognized by the immune system. This study focused on combining epitopes identified in several structural proteins into nucleic acid vaccine candidates and assessing their potential for follow-up experiments.
Key Findings: 28 Epitopes Selected from Six Proteins
The researchers obtained reference sequences for six structural proteins from the NCBI Virus database. They then used tools from the Immune Epitope Database (IEDB) to predict B-cell epitopes and epitopes associated with major histocompatibility complex (MHC) classes I and II, and assessed antigenicity, allergenicity, toxicity, and structural stability. The final selection comprised 28 epitopes.
The chimeric protein designs combining these epitopes included both protein-specific constructs and an integrated construct containing epitopes from all six proteins. PADRE and beta-defensin were also included as elements to support immune responses. The constructs were predicted to have high antigenicity and were classified in computational assessments as non-toxic and non-allergenic. The analysis also suggested the potential for strong binding to innate immune receptors, particularly Toll-like receptor 2 (TLR-2). However, the abstract provides no specific binding-affinity values, and these predictions do not establish safety in living organisms.
Immune simulations predicted strong humoral and cellular immune responses after three doses. This should be distinguished from data measuring antibody responses or protection against infection in vaccinated people. The provided abstract does not report the dose, dosing interval, or quantitative immune-response values.
The researchers also designed the constructs as nucleic acid vaccine candidates. This included in silico cloning into the pET-28a(+) vector for protein expression, codon optimization for humans, and in silico cloning of DNA constructs into the pVAX1 vector. RNAfold was used to predict the secondary structure of mRNA transcripts. These are sequence and construct design results; the abstract provides no basis for interpreting them as confirmation of actual protein expression levels or successful manufacturing.
Significance and Outlook: Experimental Validation of Predicted Candidates
This study proposed epitopes and protein-specific and integrated constructs for consideration in HMPV vaccine development. The researchers also noted that the selected epitopes might contribute to the development of diagnostic tools and infection-surveillance strategies, but they did not present results validating diagnostic accuracy or clinical utility.
Follow-up studies must determine whether the predicted properties are reproduced experimentally. Construct expression, immune responses, protection against infection, and safety each require validation. The provided abstract is insufficient to determine whether these candidates outperform existing vaccine candidates or protect high-risk groups. The study was published in Scientific Reports; the evidence reviewed here is limited to the provided Europe PMC bibliographic record and abstract.
Nucleic acid-based vaccines have emerged as powerful tools in combating both emerging and re-emerging viral pathogens. Among these, Human metapneumovirus (HMPV) is a respiratory pathogen that predominantly affects children, immunocompromised individuals, and the elderly. A major outbreak in China in 2025 renewed global concern, particularly due to the lack of licensed vaccines or antiviral therapies for HMPV, despite its widespread circulation and clinical significance. In this study, we aimed to design multi-epitope, DNA and mRNA vaccine candidates targeting HMPV structural proteins using a reverse vaccinology approach. Reference sequences of six structural proteins were retrieved from the NCBI Virus database. B-cell, MHC-I, and MHC-II epitopes were predicted using IEDB tools, followed by evaluation of antigenicity, allergenicity, toxicity, and structural stability. Twenty-eight epitopes were selected to construct chimeric proteins, incorporating adjuvants such as PADRE and Ξ²-defensin, individually for each protein and in a global construct combining epitopes from all proteins. The constructs showed high predicted antigenicity, no toxicity or allergenicity, and strong binding affinity to innate immune receptors, particularly TLR-2. Immune simulations predicted robust humoral and cellular responses after three doses. In silico cloning into pET-28a(+) enabled heterologous protein expression. Codon optimization for Homo sapiens and in silico cloning of the DNA construct into the pVAX1 vector were realized. Finally, the secondary structure of the mRNA transcript was predicted using RNAfold. These findings support the potential of these in silico-designed vaccines against HMPV, particularly for high-risk populations. Selected epitopes may also contribute to the development of diagnostic tools and enhanced surveillance strategies.
Vaccine researchers can consider the proposed protein-specific and integrated constructs as starting points for follow-up experiments. For example, they could produce the candidates, compare whether they are expressed and the immune responses they elicit, and then assess protection against infection. This is a possible follow-up research scenario for validating computational predictions, not work completed in the present study.
The authors also proposed potential diagnostic applications for the selected epitopes. Diagnostic performance in actual samples would need separate validation. The current results do not establish that a vaccine or diagnostic test is available for patient use, and they do not determine preventive efficacy or safety in living organisms in children, immunocompromised people, or older adults.